Clinical Trial Update: Safety and Effectiveness of Apixaban in Very Elderly Patients With Non-valvular Atrial Fibrillation (NVAF) Compared to Warfarin Using Administrative Claims Data

View source ↗

Summary

A Pfizer-sponsored analysis evaluates safety and effectiveness of apixaban versus warfarin in very elderly patients with non-valvular atrial fibrillation using …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-valvular Atrial Fibrillation

Drugs mentioned

• Eliquis (apixaban)

Snippet

Sponsor: Pfizer | Conditions: Non-valvular Atrial Fibrillation | Status: COMPLETED | Results posted: 2024-05-20